Opioid Addiction Treatment Denied by Insurance: Your Legal Rights

Opioid use disorder (OUD) is a medical condition with proven, life-saving treatments. Yet insurance denials for medications for opioid use disorder (MOUD), medically supervised detox, and residential rehabilitation remain shockingly common. If you or someone you love has been denied coverage for Suboxone (buprenorphine/naloxone), methadone, Sublocade, residential treatment, or detox services, federal law is almost certainly on your side.

What Is Being Denied — and Why It Matters

Buprenorphine (Suboxone, Subutex, Sublocade): This FDA-approved MOUD dramatically reduces opioid overdose death risk. Despite this, insurers deny it through step therapy requirements (requiring failure of other treatments first), quantity limits, Prior Authorization Denied: How to Appeal" class="auto-link">prior authorization delays, or refusal to cover extended-release formulations. Some plans require repeated drug testing or counseling session attendance as a condition of continued coverage — requirements that go beyond clinical guidelines and often constitute Mental Health Parity Act (MHPAEA) Explained" class="auto-link">MHPAEA violations.

Methadone for OUD: Methadone dispensed at opioid treatment programs (OTPs) is the most evidence-based treatment for severe OUD. Medicaid covers it in most states; commercial coverage is more variable. Denials often cite that the OTP is out-of-network.

Medically Supervised Withdrawal (Detox): Some insurers limit detox to a set number of days regardless of clinical presentation, or deny outpatient detox for patients with comorbid conditions who could safely complete it at lower intensity. Arbitrary day limits that are applied to OUD detox but not to other medical detox situations (e.g., alcohol or benzodiazepine detox) may violate MHPAEA.

Residential Rehabilitation: Insurance plans frequently deny residential rehab for OUD by citing lack of medical necessity or requiring failure of outpatient treatment first, even when the patient is at high risk of relapse or overdose in a lower level of care.

The Legal Framework You Can Invoke

MHPAEA (Mental Health Parity and Addiction Equity Act): Substance use disorders, including opioid use disorder, are covered under MHPAEA parity protections. Your insurer cannot apply more restrictive prior authorization, day limits, step therapy, or medical necessity criteria to OUD treatment than it applies to comparable medical/surgical benefits.

The Departments of Labor, Treasury, and Health and Human Services have published explicit guidance — including a 2023 NQTL Final Rule — making clear that MHPAEA violations related to SUD treatment are an enforcement priority. If your plan denies methadone or buprenorphine with restrictions that would not apply to a comparable chronic medical medication, document and report it.

The SUPPORT Act and ACA: Federal law requires Medicaid plans and ACA marketplace plans to cover substance use disorder treatment. ACA Essential Health Benefits include mental health and SUD services. Non-grandfathered individual and small group plans cannot exclude OUD treatment.

State Mandates: Many states have enacted additional protections. Several states (including California, New York, Massachusetts, Connecticut) have enacted laws requiring commercial insurance to cover MOUD without prior authorization. Check your state's specific mandates.

Building Your MOUD Appeal

Prior authorization delays: If you are waiting for prior authorization approval for buprenorphine and the delay creates immediate risk, request an urgent/expedited review. For life-threatening situations, your provider can also override through an emergency dispensing protocol.

Quantity limit denials: Buprenorphine quantity limits must be clinically justified. ASAM's National Practice Guideline does not support arbitrary dose caps. Your prescriber should document why the prescribed dose is medically necessary based on your specific clinical presentation.

Step therapy overrides: If your insurer requires you to first try and fail another treatment before approving buprenorphine, cite the SUPPORT Act's step therapy protections and the evidence that delaying MOUD increases overdose risk.

Residential rehab denials: Use ASAM's Level of Care criteria as the evidence base. ASAM Criteria are the gold standard for SUD level-of-care determinations and are specifically recognized in many state regulations. Your treatment provider should complete an ASAM Criteria assessment and submit it with the appeal.

The Appeal Process

1. Obtain the complete denial letter with the specific clinical criteria used
2. Have your prescribing physician or treatment counselor write a letter of medical necessity responding directly to the stated denial reason
3. Request a peer-to-peer review between your provider and the insurer's medical reviewer
4. File an internal appeal within the plan's deadline (typically 180 days for non-urgent, 72 hours for urgent concurrent denials)
5. If internal appeal fails, request an independent External Independent Review: Complete Guide" class="auto-link">external review
6. File complaints with your state insurance commissioner and the Department of Labor (ERISA plans)

Document everything. Each step of the denial and appeal process creates a record that is valuable if you need to escalate to a regulatory complaint or legal action.

Fight Back With ClaimBack

Opioid use disorder treatment saves lives. If your insurer is standing in the way, you have powerful legal tools to fight back. ClaimBack helps you structure an appeal that speaks the language insurers respond to.

Start your opioid use disorder insurance appeal at ClaimBack

Related Reading

• How to Write an Insurance Appeal Letter That Gets Results
• What Is Medical Necessity — and How to Prove It to Your Insurer
• Common Reasons Insurance Claims Are Denied